Inventor · disambiguated record
Rhys Salter
Also filed as: SALTER RHYS
31 granted patents·13 pending applications·164 citations·filing 2004–2025
96Inventor score
Files withJANSSEN PHARMACEUTICA NV27JANSSEN BIOTECH INC10ORTHO CLINICAL DIAGNOSTICS INC3SALTER RHYS2AUBERSON YVES1
Top patents by PatentIndex Score
44 records- 0197US11576986B2Macrocyclic chelators and methods of use thereofJANSSEN BIOTECH INC·Filed 2020·Granted Feb 14, 2023·9 cites·22 claims
- 0296US9611332B2Antibodies to aripiprazole haptens and use thereofJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Apr 4, 2017·18 cites·7 claims
- 0396US9494607B2Antibodies to aripiprazole and use thereofORTHO CLINICAL DIAGNOSTICS INC·Filed 2013·Granted Nov 15, 2016·17 cites·23 claims
- 0495US9795685B2Haptens of aripiprazoleJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Oct 24, 2017·17 cites·44 claims
- 0595US9410972B2Antibodies to quetiapine and use thereofORTHO CLINICAL DIAGNOSTICS INC·Filed 2013·Granted Aug 9, 2016·17 cites·20 claims
- 0694US9494608B2Antibodies to olanzapine and use thereofORTHO CLINICAL DIAGNOSTICS INC·Filed 2013·Granted Nov 15, 2016·15 cites·25 claims
- 0792US9850318B2Antibodies to quetiapine haptens and use thereofJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Dec 26, 2017·16 cites·15 claims
- 0892US9504682B2Haptens of aripiprazoleJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Nov 29, 2016·17 cites·13 claims
- 0991US9303041B2Haptens of olanzapineJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Apr 5, 2016·17 cites·29 claims
- 1091US9304126B2Haptens of quetiapineJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Apr 5, 2016·17 cites·21 claims
- 1179US9611259B2Substituted pyridine derivatives useful as C-FMS kinase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Apr 4, 2017·3 cites·13 claims
- 1278US10175257B2Antibodies to aripiprazole and use thereofJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Jan 8, 2019·1 cites·19 claims
- 1378US2024391849A1Radiolabeling of polypeptidesJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1474US2024238461A1Macrocyclic compounds and methods of use thereofJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1573US12453785B2Macrocyclic chelators and methods of use thereofJANSSEN BIOTECH INC·Filed 2022·Granted Oct 28, 2025·0 cites·18 claims
- 1672US11105793B2Antibodies to aripiprazole haptens and use thereofJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Aug 31, 2021·0 cites·11 claims
- 1771US11046786B2Antibodies to olanzapine and use thereofJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Jun 29, 2021·0 cites·20 claims
- 1871US10816561B2Antibodies to aripiprazole and use thereofJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Oct 27, 2020·0 cites·26 claims
- 1970US2021017294A9Antibodies to quetiapine haptens and use thereofJANSSEN PHARMACEUTICA NV·Filed 2019·Application pending·0 cites
- 2069US11214566B2Substituted pyridine derivatives useful as C-FMS kinase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Jan 4, 2022·0 cites·12 claims
- 2169US2019271712A1Antibodies to quetiapine and use thereofJANSSEN PHARMACEUTICA NV·Filed 2019·Application pending·0 cites
- 2267US2025171379A1Radiolabeling of polypeptidesJANSSEN BIOTECH INC·Filed 2025·Application pending·0 cites
- 2366US10488401B2Antibodies to aripiprazole haptens and use thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Nov 26, 2019·0 cites·15 claims
- 2466US2022143231A1Macrocyclic compounds and methods of use thereofJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2564US10712353B2Antibodies to olanzapine haptens and use thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Jul 14, 2020·0 cites·7 claims
- 2663US11104742B2Antibodies to quetiapine and use thereofJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Aug 31, 2021·0 cites·21 claims
- 2763US10379105B2Antibodies to aripiprazole haptens and use thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Aug 13, 2019·0 cites·8 claims
- 2862US12240790B2Radiolabeling of polypeptidesJANSSEN BIOTECH INC·Filed 2018·Granted Mar 4, 2025·0 cites·23 claims
- 2962US11226345B2Antibodies to olanzapine haptens and use thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Jan 18, 2022·0 cites·15 claims
- 3062US10800764B2Substituted pyridine derivatives useful as C-FMS kinase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2018·Granted Oct 13, 2020·0 cites·10 claims
- 3161US2025082793A1Macrocyclic compounds and methods of making the sameJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 3260US10071991B2Substituted pyridine derivatives useful as c-fms kinase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Sep 11, 2018·0 cites·3 claims
- 3359US10465013B2Antibodies to quetiapine haptens and use thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Nov 5, 2019·0 cites·14 claims
- 3459US10288631B2Antibodies to quetiapine and use thereofJANSSEN PHARMACEUTICA NV·Filed 2016·Granted May 14, 2019·0 cites·12 claims
- 3559US10166296B2Haptens of aripiprazoleJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Jan 1, 2019·0 cites·9 claims
- 3658US10344098B2Antibodies to olanzapine and use thereofJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Jul 9, 2019·0 cites·25 claims
- 3758US2023011134A1Compositions and methods for the treatment of prostate cancerJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 3857US10435478B2Antibodies to quetiapine and use thereofJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Oct 8, 2019·0 cites·25 claims
- 3957US2025145646A1Macrocyclic compounds and diagnostic uses thereofJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 4056US2014057303A1Antibodies to Olanzapine Haptens and Use ThereofJANSSEN PHARMACEUTICA NV·Filed 2013·Application pending·0 cites
- 4155US7655686B2Certain substituted spirocyclic lactams and use thereof as pharmaceuticalsNOVARTIS AG·Filed 2007·Granted Feb 2, 2010·0 cites·4 claims
- 4251US2007015781A1Certain substituted spirocyclic lactams and use thereof as pharmaceuticalsAUBERSON YVES·Filed 2004·Application pending·0 cites
- 4342US2009299064A1Methods and intermediates for the preparation of optionally radio-labeled imatinibSALTER RHYS·Filed 2006·Application pending·0 cites
- 4440US2012316338A1Methods and Intermediates for the Preparation of Optionally Radio-Labeled ImatinibSALTER RHYS·Filed 2012·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →